根据新华社的消息，有“中国天眼”之称的 500 米口径球面射电望远镜（FAST）将于 2021 年 4 月 1 日正式对全球科学界开放，8 月 1 日起分配观测时间，预计分配给国外科学家的观测时间约占 10%。
500 米口径球面射电望远镜（Five-hundred-meter Aperture Spherical radio Telescope）利用贵州喀斯特地区的洼坑作为望远镜台址建造的世界第一大单口径射电望远镜，其拥有 30 个标准足球场大的接收面积。FAST 作为世界最大的单口径望远镜，将在未来 20 至 30 年保持世界一流地位。全新的设计思路，加之得天独厚的台址优势，使其突破了望远镜的百米工程极限，开创了建造巨型射电望远镜的新模式。
去年 11 月公布的数据显示，中国天眼 FAST 已发现脉冲星数量超过 240 颗，基于 FAST 数据发表的高水平论文达到 40 余篇。
1月1日晚，上海复旦大学附属华山医院感染科主任张文宏在其个人微博发文称，上海疾控检测到第一株VOC毒株，立即向中国疾控申报，并且在中国疾控的官方杂志China CDC Weekly （中国疾控周报）上向全球发布，“这是一个常规动作，证明对于变异病毒株中国目前具备非常强的监测能力”。
张文宏医生在其博文中表示：“这个病例其实没有任何特殊，和任何一个感染了新冠病毒肺炎的其他患者没有区别。”
此外为了打消大家的疑虑。张文宏医生特地去翻看了这个患者的病历，因为没有任何特殊，所以原来根本就没有注意。“这个病例的症状非常轻微，轻微到不需要我关注。这个患者目前已经核酸转阴，离开隔离病房了。”
中国疾控中心：目前英国报道的新冠病毒变异株致病性尚无明显变化 不必恐慌.
上海发现的变异株基因检测结果表明变异株对细胞感染力增强，但在人间传播力与人类社会活动、冬季的气候和人群的自我防护措施紧密相关。
目前新冠病毒变异株与既往变异株的致病性、严重性或者病死率未见差异，致病性尚无明显变化，不必恐慌。
目前尚未发现新冠病毒变异株对我国上市的灭活新冠疫苗的免疫效力产生影响。
目前我国主流核酸诊断试剂是针对的新冠病毒双靶标基因、N基因和ORF1ab基因，蛋白基因变异不影响核酸试剂的敏感性和特异性，上海变异株就是我国本土核酸试剂检测出来的。
我国4月份阻断了本土新冠病毒的传播，之后通过境外输入的病例或污染的冷链物品导致的10多起新冠病毒肺炎聚集性疫情，都采取了有效的阻断传播措施。定期筛查高风险人群、早诊断、早治疗、早期隔离感染者和密接者，戴口罩，勤洗手，保持社交距离；是我国行之有效的阻断新冠病毒传播的有效措施。
百姓不必恐慌，一定要严格落实我国现有防控措施，需要加强个人防护意识，特别是加强针对有输入病例的医院或定点隔离酒店的医护和从业人员的防护。
According to CCTV news, as of 6:00 today, tianwen-1 Mars probe has been in orbit for 163 days, with a flight mileage of more than 400 million kilometers, about 130 million kilometers from the earth and 8.3 million kilometers from Mars.
China Aerospace Group official said that tianwen-1 Mars probe has a stable attitude, and will implement near fire braking in more than one month as planned, enter the annular fire orbit, and be ready to land on Mars.
Tianwen-1 mission is the first step of China's independent interplanetary exploration. It will realize the "orbit, landing and patrol" of Mars through a single launch, that is, Mars orbit, Mars landing and fire surface patrol.
The total weight of tianwen-1 is about 5 tons. It is composed of a orbiter and a landing Rover. The landing Rover mainly includes an entry module and a Mars rover. At present, the orbiter has completed the third on orbit self-test, and all systems are working normally.
我国5个疫苗进入Ⅲ期临床试验
发布会上，国家药品监督管理局副局长陈时飞介绍，国药集团中国生物新冠灭活疫苗已获得国家药监局批准附条件上市。已有数据显示，保护率为79.34%，实现安全性、有效性、可及性、可负担性的统一，达到世界卫生组织及国家药监局相关标准要求。后续，疫苗免疫的持久性和保护效果还需持续观察。
此外，科学技术部副部长徐南平表示，到目前为止，我国5条技术路线14个疫苗进入临床试验，其中3条技术路线5个疫苗进入Ⅲ期临床试验。
北京、湖北承担新冠疫苗批签发工作
发布会上，陈时飞表示，目前已授予北京市和湖北省药品监管和检验机构承担新冠疫苗的批签发工作。批签发机构将按照有关法规及管理办法，对每一批疫苗实行严格审核和检验，确保每一支疫苗是合格的。
发布会上，徐南平表示，科研攻关组召开多次会议，专家认为目前没有证据证明新冠变异病毒会对疫苗的使用效果造成实质性影响，但需要高度关注。
国家卫生健康委员会副主任曾益新表示，新冠病毒疫苗的基本属性是公共产品，价格根据使用规模的大小会有所变化，但是一个大前提肯定是为全民免费提供。
我国重点人群接种疫苗超300万剂次，安全性良好
发布会上，曾益新介绍新冠疫苗重点人群接种工作情况。他表示，我国疫苗研发始终属于全球第一方阵：
自12月15日正式启动重点人群接种工作以来，目前累计接种超过300万剂次。
接种结果充分证明我国疫苗安全性良好，发生了一定比例的不良反应，总的发生率与常规接种的灭活疫苗接近。
主要表现是局部疼痛、硬结，轻度发热比例大概不到0.1%，过敏等比较严重的情况为百万分之二，这些情况经过及时处理都得到很好的治疗。
接下来将全面推进老年人和有基础疾病的人群进行接种，后续再开展其他普通人群的接种，未来符合条件的群众都将实现“应接尽接”。
疫苗研发绝不会为了争第一而“抢跑”
发布会上，新冠疫苗研发专班工作组组长郑忠伟表示，疫苗研发过程是在和病毒赛跑，但我们充分尊重疫苗研发的科学规律和科学原则。
我国是最早开展临床试验，也是最早开展Ⅲ期临床试验。但是由于我国疫情控制得好，我们在境外开展临床试验，在临床试验过程中严格遵守相关规则，绝不会为了争第一而“抢跑”。
At the press conference, Chen Shifei, deputy director of the State Drug Administration, said that Sinopharm's China Bio new crown inactivated vaccine had been approved by the State Drug Administration for conditional marketing. The existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, meeting the relevant standards of who and SFDA. In the future, the persistence and protective effect of the vaccine should be observed continuously.
In addition, Xu Nanping, Vice Minister of the Ministry of science and technology, said that so far, 14 vaccines from five technical routes have entered clinical trials in China, of which five vaccines from three technical routes have entered phase III clinical trials.
Grant of new vaccines in Beijing and Hubei
At the press conference, Chen Shifei said that the drug regulatory and inspection institutions in Beijing and Hubei Province have been awarded the task of issuing the new crown vaccine in batches. In accordance with relevant regulations and administrative measures, the batch issuing agency will strictly audit and inspect each batch of vaccines to ensure that each vaccine is qualified.
At the press conference, Xu Nanping said that the scientific research team has held many meetings, and experts believe that there is no evidence that the new coronavirus mutation will have a substantial impact on the use of the vaccine, but it needs high attention.
Zeng Yixin, deputy director of the National Health Commission, said that the basic attribute of the new coronavirus vaccine is public goods, and the price will change according to the scale of use, but one major premise is definitely to provide free for all.
Over 3 million doses of the vaccine have been given to key population in China, with good safety
At the press conference, Zeng Yixin introduced the vaccination work of key groups of Xinguan vaccine. He said that China's vaccine research and development has always been the first in the world
Since the official launch of vaccination work for key population on December 15, the cumulative number of inoculations has exceeded 3 million.
The results of vaccination fully proved that the safety of vaccine in China was good, a certain proportion of adverse reactions occurred, and the total incidence was close to that of conventional inactivated vaccine.
The main performance is local pain, induration, mild fever rate is less than 0.1%, allergy and other serious situation is two parts per million, these situations after timely treatment are very good treatment.
Next, we will comprehensively promote the vaccination of the elderly and people with basic diseases, and then carry out the vaccination of other ordinary people. In the future, all the eligible people will be able to "receive as much as possible.".
Sinopharm China Biological New Crown inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing
At the press conference, Zheng Zhongwei, head of the working group of new crown vaccine research and development, said that the vaccine research and development process is a race against the virus, but we fully respect the scientific laws and principles of vaccine research and development.
China is the first to carry out clinical trials, and also the first to carry out phase III clinical trials. However, due to the good control of the epidemic situation in our country, we carry out clinical trials abroad, strictly abide by the relevant rules in the process of clinical trials, and will never "rush" for the first place.
小任班长的博客 